Previous Section
Clinical Trials
11. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
- Author
- Kantarjian H; Issa JP; Rosenfeld CS; Bennett JM; Albitar M; DiPersio J; Klimek V; Slack J; de Castro C; Ravandi F; Helmer R 3rd; Shen L; Nimer SD; Leavitt R; Raza A; Saba H;
- Institution
- Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. hkantarj@mdanderson.org
- Journal
- Cancer. 2006 Apr 15;106(8):1794-803.
- Abstract URL
- Click here to view abstract
12. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients.
- Author
- Ruter B; Wijermans PW; Lubbert M;
- Institution
- Division of Hematology/Oncology, Department of Internal Medicine I, Albert-Ludwigs-University Freiburg, Freiburg, Germany.
- Journal
- Cancer. 2006 Apr 15;106(8):1744-50.
- Abstract URL
- Click here to view abstract
13. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.
- Author
- Martino R; Iacobelli S; Brand R; Jansen T; van Biezen A; Finke J; Bacigalupo A; Beelen D; Reiffers J; Devergie A; Alessandrino E; Mufti GJ; Barge R; Sierra J; Ruutu T; Boogaerts M; Falda M; Jouet JP; Niederwieser D; de Witte T;
- Institution
- Division of Clinical Hematology, Hopital de la Sant Creu i Sant Pau, Autonomous University of Barcelona, Spain. rmartino@santpau.es
- Journal
- Blood. 2006 Aug 1;108(3):836-46. Epub 2006 Apr 4.
- Abstract URL
- Click here to view abstract
14. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
- Author
- Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P; Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P;
- Institution
- Institut Paoli-Calmettes, Marseille, France. veyn@marseille.fnclcc.fr
- Journal
- J Clin Oncol. 2006 Jun 1;24(16):2465-71. Epub 2006 May 1.
- Abstract URL
- Click here to view abstract
15. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
- Author
- Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF; Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF;
- Institution
- UCLA Division of Hematology-Oncology, University of California Los Angeles, San Diego, CA 90095, USA. garyjs@ucla.edu
- Journal
- J Clin Oncol. 2006 Jun 1;24(16):2456-64. Epub 2006 May 1.
- Abstract URL
- Click here to view abstract
16. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study.
- Author
- Mannone L; Gardin C; Quarre MC; Bernard JF; Vassilieff D; Ades L; Park S; Vaultier S; Hamza F; Beyne-rauzy MO; Cheze S; Giraudier S; Agape P; Legros L; Voillat L; Dreyfus F; Fenaux P; Mannone L; Gardin C; Quarre MC; Bernard JF; Vassilieff D; Ades L; Park S; Vaultier S; Hamza F; Beyne-rauzy MO; Cheze S; Giraudier S; Agape P; Legros L; Voillat L; Dreyfus F; Fenaux P;
- Institution
- Department of Haematology, Nice University Hospital, Nice, France.
- Journal
- Br J Haematol. 2006 Jun;133(5):513-9.
- Abstract URL
- Click here to view abstract
17. Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes.
- Author
- Musto P; Falcone A; Sanpaolo G; Bodenizza C; Musto P; Falcone A; Sanpaolo G; Bodenizza C;
- Institution
- Hematology and Stem Cell Transplantation Unit, IRCCS "Casa Sollievo della Sofferenza" Hospital, I-71013, S. Giovanni Rotondo, Italy. p.musto@tin.it
- Journal
- Leuk Res. 2006 Apr;30(4):385-8. Epub 2005 Oct 10.
- Abstract URL
- Click here to view abstract
18. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity.
- Author
- Shimoni A; Hardan I; Shem-Tov N; Yeshurun M; Yerushalmi R; Avigdor A; Ben-Bassat I; Nagler A; Shimoni A; Hardan I; Shem-Tov N; Yeshurun M; Yerushalmi R; Avigdor A; Ben-Bassat I; Nagler A;
- Institution
- The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel. ashimoni@sheba.health.gov.il
- Journal
- Leukemia. 2006 Feb;20(2):322-8.
- Abstract URL
- Click here to view abstract
19. Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes.
- Author
- Raza A; Lisak L; Billmeier J; Pervaiz H; Mumtaz M; Gohar S; Wahid K; Galili N;
- Institution
- The Radhey Khanna Center for MDS Research, University of Massachusetts Medical Center, Worcester, MA 01605, USA. azra.raza@umass.edu
- Journal
- Leuk Lymphoma. 2006 Mar;47(3):433-40.
- Abstract URL
- Click here to view abstract
20. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
- Author
- Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R; Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R;
- Institution
- Department of Hematology and Oncology, University of Genoa, Azienda Ospedaliera Universitaria San Martino di Genova, Genoa, Italy.
- Journal
- Ann Hematol. 2006 Mar;85(3):174-80. Epub 2006 Jan 12.
- Abstract URL
- Click here to view abstract
